Skip to main content

Pharmaceutical Products

Volume 455: debated on Tuesday 16 January 2007

To ask the Secretary of State for Health what assessment she has made of the likely financial effect upon the NHS of changes to the distribution of pharmaceutical products by (a) AstraZeneca and (b) Lilly. (113388)

Officials understand that neither company has finalised any changes to their distribution arrangements.

The Department will monitor any new arrangements. If the changes result in shortages, disruptions to supply, any additional costs to the national health service, or has a detrimental affect on funding pharmacy contractors then the Department will seek to ensure the corrective action is taken.